Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune... see more

TSX:ONC - Post Discussion

Oncolytics Biotech Inc > BRACELET-1 Time Line
View:
Post by Spdstr on Sep 14, 2022 2:00am

BRACELET-1 Time Line

Brad stated at the Q2 Conf Call that Oncolytics plans on announcing BRACELET-1’s full suite of clinical and translational data alongside emerging overall survival results at a major medical meeting in Q2 2023, which I'm guessing would be the ASCO meeting scheduled for June 2-6.  This is 3 to 4 months after the 90-day Pfizer exclusivity period will be completed. 

Here is the estimated time line
The BRACELET-1 enrolment  was completed near the end of  Q2 2022.
The primary endpoint of the week 16 overall response rate should be completed by end of Oct.
Assuming one to two months for the cleaned and locked the database, this should be completed sometime in Nov or Dec which will trigger the start of their 90-day period of exclusivity.
In which case the 90-day Exclusitivity period should completed sometime in Feb or Mar 2023.
This 3 to 4 months before the ASCO meeting but lines up with the ASCO abstract deadline of Feb 14.

This is speculation, if Pfizer doesn't come up with an acceptable offer after the 90 day exclusivity period, Oncolytics will use this 3 to 4 month period fo set up a bidding war with other potentail partners with a major announcement at ASCO.
 
 
Comment by westcoast1000 on Sep 14, 2022 2:05am
spdstr, Thanks for the stimulating post. An aside: now it is Matt as CEO, not Brad. I sometimes make the same mistake. 
Comment by westcoast1000 on Sep 14, 2022 2:06am
spdstr, Thanks for the stimulating post. An aside: now it is Matt as CEO, not Brad. I sometimes make the same mistake.
Comment by Spdstr on Sep 14, 2022 2:34am
oops, I've been in ONCY too long
Comment by Noteable on Sep 14, 2022 11:10am
The Bracelet-1 study investigators announced full enrollment at the end of June 2022.. With 16 weeks of analysis (if required) and with a 3 month (90 days) stand-still option to Pfizer/Merck KGaA brings the full time line to the end of January 2023. It would seem probable that Pfizer or MerckKGaA moves to acquire ONCY before the end of this process so that they could prepare to the full dataset ...more  
Comment by Noteable on Sep 14, 2022 11:26am
Should read: "...brings the full time line to the end of January 2023, if required."
Comment by fox7mf on Sep 14, 2022 4:57pm
Agreed...and as Noteable has astutely pointed out numerous times, BP likes to wrap up M&A activities before the end of the calendar year in which negotiations started. I imagine Q4 '22 will be our time
Comment by Buckhenry on Sep 14, 2022 10:03pm
i dont know how many times I have heard ... this is our time.... over the last numteen years... so pardon me if I dont get a woody over all this speculation on here.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities